Atrophic vaginitis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Atrophic vaginitis Classification and external resources | |
| ICD-10 | N95.2 |
|---|---|
| ICD-9 | 627.3 |
| DiseasesDB | 32516 |
| MedlinePlus | 000892 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Atrophic vaginitis (also known as vaginal atrophy or urogenital atrophy) is an inflammation of the vagina (and the outer urinary tract) due to the thinning and shrinking of the tissues, as well as decreased lubrication. This is all due to a lack of the reproductive hormone estrogen.
The most common cause of vaginal atrophy is the decrease in estrogen which happens naturally during perimenopause, and increasingly so in post-menopause. However this condition can sometimes be caused by other circumstances.
The symptoms include vaginal soreness and itching, as well as painful intercourse, and bleeding after sexual intercourse. The shrinkage of the tissues can be extreme enough to make intercourse impossible.
Symptoms and signs
Genital symptoms include dryness, itching, burning, soreness, pressure, thick yellow white discharge, malodorous discharge, infection, painful sexual intercourse, bleeding after intercourse. In addition, sores and cracks may occur.
Urinary symptoms include painful urination, blood in the urine, increased frequency of urination, incontinence, and increased likelihood and occurrence of infections.
Incidence and causes
A large number of postmenopausal women (who are not using topical estrogen) have at least some degree of vaginal atrophy, however, many women do not actively ask that medical attention be paid to this, possibly because it is naturally caused, or because of the taboo that still exists surrounding aging and sexuality.
The cause of vaginal atrophy is usually the normal decrease in estrogen as a result of menopause. Other causes of decreased estrogen are decreased ovarian functioning due to radiation therapy or chemotherapy, immune disorder, removal of the ovaries, after pregnancy, during lactation, idiopathic, and because of the effects of various medications (Tamoxifen (Nolvadex), Danazol (Danocrine), Medroxyprogesterone (Provera), Leuprolide (Lupron), Nafarelin (Synarel)).
Treatment
Topical estrogen creams or tablets may be used vaginally. Oral or transdermal estrogen may be used. See Boxed Warning about estrogen therapy below.
Sexual activity is also helpful. A water-soluble vaginal lubricant may be useful.
Boxed Warning
The labeling of estrogen-only products includes a boxed warning that unopposed estrogen (without progestin) therapy increases the risk of endometrial cancer.
Based on a review of data from the WHI, on January 8 2003 the FDA changed the labeling of all estrogen and estrogen with progestin products for use by postmenopausal women to include a new boxed warning about cardiovascular and other risks. The estrogen-alone sub-study of the WHI reported an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women 50 years of age or older and an increased risk of dementia in postmenopausal women 65 years of age or older using 0.625 mg of Premarin conjugated equine estrogens (CEE). The estrogen-plus-progestin substudy of the WHI reported an increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and DVT in postmenopausal women 50 years of age or older and an increased risk of dementia in postmenopausal women 65 years of age or older using 0.625 mg of CEE with 2.5 mg of the progestin medroxyprogesterone acetate (MPA).[1][1][1]
Prognosis
Proper treatment will usually relieve the symptoms, at least to some extent.
Prevention
Use of vaginal estrogen before the condition becomes severe is appropriate. Regular sexual activity may be helpful. A water soluble vaginal lubricant can be helpful in mild cases.
Notes
References
Bachmann M.D., Gloria (05-15-2000). Diagnosis and Treatment of Atrophic vaginitis. American Academy of Family Physicians. Retrieved on 2006-09-18.
Vaginal Atrophy (Atrophic vaginitis) (02-03-2006). Retrieved on 2006-09-18.
WikiDoc Research Resources for Atrophic vaginitis | |
|---|---|
| Articles on Atrophic vaginitis | Most recent articles on Atrophic vaginitis • Most cited articles on Atrophic vaginitis • Review articles on Atrophic vaginitis • Articles on Atrophic vaginitis in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Atrophic vaginitis | Powerpoint slides on Atrophic vaginitis • Images of Atrophic vaginitis • Photos of Atrophic vaginitis • Podcasts & MP3s on Atrophic vaginitis • Videos on Atrophic vaginitis |
| Evidence Based Medicine Regarding Atrophic vaginitis | Cochrane Collaboration on Atrophic vaginitis • Bandolier on Atrophic vaginitis • TRIP on Atrophic vaginitis |
| Cost Effectiveness of Atrophic vaginitis | Cost Effectiveness of Atrophic vaginitis |
| Clinical Trials Involving Atrophic vaginitis | Ongoing Trials on Atrophic vaginitis at Clinical Trials.gov • Trial results on Atrophic vaginitis • Clinical Trials on Atrophic vaginitis at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Atrophic vaginitis | US National Guidelines Clearinghouse on Atrophic vaginitis • NICE Guidance on Atrophic vaginitis • NHS PRODIGY Guidance • FDA on Atrophic vaginitis • CDC on Atrophic vaginitis |
| Textbook Information on Atrophic vaginitis | Books and Textbook Information on Atrophic vaginitis |
| Pharmacology Resources on Atrophic vaginitis | Dosing of Atrophic vaginitis • Drug interactions with Atrophic vaginitis • Side effects of Atrophic vaginitis • Allergic reactions to Atrophic vaginitis • Overdose information on Atrophic vaginitis • Carcinogenicity information on Atrophic vaginitis • Atrophic vaginitis in pregnancy • Pharmacokinetics of Atrophic vaginitis • |
| Genetics, Pharmacogenomics, and Proteinomics of Atrophic vaginitis | Genetics of Atrophic vaginitis • Pharmacogenomics of Atrophic vaginitis • Proteomics of Atrophic vaginitis |
| Newstories on Atrophic vaginitis | Atrophic vaginitis in the news • Be alerted to news on Atrophic vaginitis • News trends on Atrophic vaginitis |
| Commentary on Atrophic vaginitis | Blogs on Atrophic vaginitis |
| Patient Resources on Atrophic vaginitis | Patient resources on Atrophic vaginitis • Discussion groups on Atrophic vaginitis • Patient Handouts on Atrophic vaginitis • Directions to Hospitals Treating Atrophic vaginitis • Risk calculators and risk factors for Atrophic vaginitis |
| Healthcare Provider Resources on Atrophic vaginitis | Symptoms of Atrophic vaginitis • Causes & Risk Factors for Atrophic vaginitis • Diagnostic studies for Atrophic vaginitis • Treatment of Atrophic vaginitis |
| Continuing Medical Education (CME) Programs on Atrophic vaginitis | CME Programs on Atrophic vaginitis |
| International Resources on Atrophic vaginitis | Atrophic vaginitis en Espanol • Atrophic vaginitis en Francais |
| Business Resources on Atrophic vaginitis | Atrophic vaginitis in the Marketplace • Patents on Atrophic vaginitis |
| Informatics Resources on Atrophic vaginitis | List of terms related to Atrophic vaginitis |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
